Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF ) Freely available
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (51)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Pirwany, I.R.
Right arrow Articles by Fleming, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pirwany, I.R.
Right arrow Articles by Fleming, R.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 14, No. 12, 2963-2968, December 1999
© 1999 European Society of Human Reproduction and Embryology

Effects of the insulin sensitizing drug metformin on ovarian function, follicular growth and ovulation rate in obese women with oligomenorrhoea

I.R. Pirwany1, R.W.S. Yates, I.T. Cameron and R. Fleming

University Department of Obstetrics and Gynaecology, Glasgow Royal Infirmary, 10 Alexandra Parade, Glasgow G31 2ER, UK

Hyperinsulinaemic insulin resistance is commonly associated with hyperandrogenaemia, and menstrual dysfunction. The aim of this study was to examine the effects of the insulin sensitizing drug, metformin, on ovarian function, follicular growth, and ovulation rate in obese women with oligomenorrhoea. Twenty obese subjects with oligomenorrhoea [polycystic ovarian syndrome; (PCOS)] were observed longitudinally for 3 weeks prior to and for 8 weeks during treatment with metformin (850 mg twice per day). Fifteen patients completed the study. The frequency of ovulation was significantly higher during treatment than before treatment (P = 0.003). A significant decline in both testosterone and luteinizing hormone concentrations was recorded within 1 week of commencing treatment. Patients with elevated pretreatment testosterone concentrations showed the most marked increase in ovulation rate (P < 0.005), and significant reductions in circulating testosterone from 1.02 to 0.54 ng/ml (P < 0.005) after only 1 week of treatment. However, the sub-group with raised fasting insulin showed less marked changes, and the sub-group with normal testosterone concentrations showed no effect of treatment. Metformin had a rapid effect upon the abnormal ovarian function in hyperandrogenic women with PCOS, correcting the disordered ovarian steroid metabolism and ovulation rate; however, there appeared to be no effect in cases where the circulating androgen concentration was normal.

Key words: hyperandrogenism/metformin/ovulation/polycystic ovarian syndrome

1 To whom correspondence should be addressed at: Bellshill Maternity Hospital, North Road, Bellshill, Lanarkshire ML4 3JN, UK


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Hum ReprodHome page
M. Metwally, S. Amer, T.C. Li, and W.L. Ledger
An RCT of metformin versus orlistat for the management of obese anovulatory women
Hum. Reprod., April 1, 2009; 24(4): 966 - 975.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
N. A. Cataldo, H. X. Barnhart, R. S. Legro, E. R. Myers, W. D. Schlaff, B. R. Carr, M. P. Diamond, S. A. Carson, M. P. Steinkampf, C. Coutifaris, et al.
Extended-Release Metformin Does Not Reduce the Clomiphene Citrate Dose Required to Induce Ovulation in Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab., August 1, 2008; 93(8): 3124 - 3127.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
S. Eisenhardt, N. Schwarzmann, V. Henschel, A. Germeyer, M. von Wolff, A. Hamann, and T. Strowitzki
Early Effects of Metformin in Women with Polycystic Ovary Syndrome: A Prospective Randomized, Double-Blind, Placebo-Controlled Trial
J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 946 - 952.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
T. Tang, J. Glanville, C. J. Hayden, D. White, J. H. Barth, and A. H. Balen
Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study
Hum. Reprod., January 1, 2006; 21(1): 80 - 89.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
N. A. Cataldo, F. Abbasi, T. L. McLaughlin, M. Basina, P. Y. Fechner, L. C. Giudice, and G. M. Reaven
Metabolic and ovarian effects of rosiglitazone treatment for 12 weeks in insulin-resistant women with polycystic ovary syndrome
Hum. Reprod., January 1, 2006; 21(1): 109 - 120.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
S. Palomba, F. Orio Jr., L. G. Nardo, A. Falbo, T. Russo, D. Corea, P. Doldo, G. Lombardi, A. Tolino, A. Colao, et al.
Metformin Administration Versus Laparoscopic Ovarian Diathermy in Clomiphene Citrate-Resistant Women with Polycystic Ovary Syndrome: A Prospective Parallel Randomized Double-Blind Placebo-Controlled Trial
J. Clin. Endocrinol. Metab., October 1, 2004; 89(10): 4801 - 4809.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
C.J. Glueck, N. Goldenberg, J. Pranikoff, M. Loftspring, L. Sieve, and P. Wang
Height, weight, and motor-social development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on and continued metformin through pregnancy
Hum. Reprod., June 1, 2004; 19(6): 1323 - 1330.
[Abstract] [Full Text] [PDF]


Home page
Clin Med ResHome page
M. T. Sheehan
Polycystic Ovarian Syndrome: Diagnosis and Management
Clin. Med. Res., February 1, 2004; 2(1): 13 - 27.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
M. S. Coffler, K. Patel, M. H. Dahan, R. Y. Yoo, P. J. Malcom, and R. J. Chang
Enhanced Granulosa Cell Responsiveness to Follicle-Stimulating Hormone during Insulin Infusion in Women with Polycystic Ovary Syndrome Treated with Pioglitazone
J. Clin. Endocrinol. Metab., December 1, 2003; 88(12): 5624 - 5631.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
C. A. Eagleson, A. B. Bellows, K. Hu, M. B. Gingrich, and J. C. Marshall
Obese Patients with Polycystic Ovary Syndrome: Evidence that Metformin Does Not Restore Sensitivity of the Gonadotropin-Releasing Hormone Pulse Generator to Inhibition by Ovarian Steroids
J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5158 - 5162.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
K. Patel, M. S. Coffler, M. H. Dahan, R. Y. Yoo, M. A. Lawson, P. J. Malcom, and R. J. Chang
Increased Luteinizing Hormone Secretion in Women with Polycystic Ovary Syndrome Is Unaltered by Prolonged Insulin Infusion
J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5456 - 5461.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
V. De Leo, A. la Marca, and F. Petraglia
Insulin-Lowering Agents in the Management of Polycystic Ovary Syndrome
Endocr. Rev., October 1, 2003; 24(5): 633 - 667.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
L. A. Stadtmauer, B. C. Wong, and S. Oehninger
Should patients with polycystic ovary syndrome be treated with metformin?: Benefits of insulin sensitizing drugs in polycystic ovary syndrome--beyond ovulation induction
Hum. Reprod., December 1, 2002; 17(12): 3016 - 3026.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
E. Seli and A. J. Duleba
Should patients with polycystic ovarian syndrome be treated with metformin?
Hum. Reprod., September 1, 2002; 17(9): 2230 - 2236.
[Abstract] [Full Text] [PDF]


Home page
BMJHome page
D J Cahill and P G Wardle
Management of infertility
BMJ, July 6, 2002; 325(7354): 28 - 32.
[Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
R. Fleming, Z. E. Hopkinson, A. M. Wallace, I. A. Greer, and N. Sattar
Ovarian Function and Metabolic Factors in Women with Oligomenorrhea Treated with Metformin in a Randomized Double Blind Placebo-Controlled Trial
J. Clin. Endocrinol. Metab., February 1, 2002; 87(2): 569 - 574.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
H. Yarali, B. O. Yildiz, A. Demirol, H. B. Zeyneloglu, N. Yigit, O. Bukulmez, and Z. Koray
Co-administration of metformin during rFSH treatment in patients with clomiphene citrate-resistant polycystic ovarian syndrome: a prospective randomized trial
Hum. Reprod., February 1, 2002; 17(2): 289 - 294.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
L. Ibanez, C. Valls, A. Ferrer, M. V. Marcos, F. Rodriguez-Hierro, and F. de Zegher
Sensitization to Insulin Induces Ovulation in Nonobese Adolescents with Anovulatory Hyperandrogenism
J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3595 - 3598.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
E. H. Y. Ng, N. M. S. Wat, and P. C. Ho
Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene-resistant polycystic ovaries: a randomized, double-blinded placebo-controlled trial
Hum. Reprod., August 1, 2001; 16(8): 1625 - 1631.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
R. Azziz, D. Ehrmann, R. S. Legro, R. W. Whitcomb, R. Hanley, A. G. Fereshetian, M. O’Keefe, and M. N. Ghazzi
Troglitazone Improves Ovulation and Hirsutism in the Polycystic Ovary Syndrome: A Multicenter, Double Blind, Placebo-Controlled Trial
J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1626 - 1632.
[Abstract] [Full Text]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.